Literature DB >> 25538239

Dimeric quaternary structure of human laforin.

Rajeshwer S Sankhala1, Adem C Koksal2, Lan Ho1, Felix Nitschke3, Berge A Minassian4, Gino Cingolani5.   

Abstract

The phosphatase laforin removes phosphate groups from glycogen during biosynthetic activity. Loss-of-function mutations in the gene encoding laforin is the predominant cause of Lafora disease, a fatal form of progressive myoclonic epilepsy. Here, we used hybrid structural methods to determine the molecular architecture of human laforin. We found that laforin adopts a dimeric quaternary structure, topologically similar to the prototypical dual specificity phosphatase VH1. The interface between the laforin carbohydrate-binding module and the dual specificity phosphatase domain generates an intimate substrate-binding crevice that allows for recognition and dephosphorylation of phosphomonoesters of glucose. We identify novel molecular determinants in the laforin active site that help decipher the mechanism of glucan phosphatase activity.
© 2015 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Dual Specificity Phosphoprotein; Epilepsy; Glycogen; Lafora Disease; Laforin; Neurodegenerative Disease; Phosphatase; Phosphorylation

Mesh:

Substances:

Year:  2014        PMID: 25538239      PMCID: PMC4335197          DOI: 10.1074/jbc.M114.627406

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  45 in total

Review 1.  Molecular reactions of protein phosphatases--insights from structure and chemistry.

Authors:  M D Jackson; J M Denu
Journal:  Chem Rev       Date:  2001-08       Impact factor: 60.622

Review 2.  Progressive myoclonus epilepsy with polyglucosan bodies: Lafora disease.

Authors:  Berge A Minassian
Journal:  Adv Neurol       Date:  2002

3.  Restoring low resolution structure of biological macromolecules from solution scattering using simulated annealing.

Authors:  D I Svergun
Journal:  Biophys J       Date:  1999-06       Impact factor: 4.033

4.  UCSF Chimera--a visualization system for exploratory research and analysis.

Authors:  Eric F Pettersen; Thomas D Goddard; Conrad C Huang; Gregory S Couch; Daniel M Greenblatt; Elaine C Meng; Thomas E Ferrin
Journal:  J Comput Chem       Date:  2004-10       Impact factor: 3.376

5.  A unique carbohydrate binding domain targets the lafora disease phosphatase to glycogen.

Authors:  Jianyong Wang; Jeanne A Stuckey; Matthew J Wishart; Jack E Dixon
Journal:  J Biol Chem       Date:  2001-12-05       Impact factor: 5.157

6.  Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association.

Authors:  J O Lee; H Yang; M M Georgescu; A Di Cristofano; T Maehama; Y Shi; J E Dixon; P Pandolfi; N P Pavletich
Journal:  Cell       Date:  1999-10-29       Impact factor: 41.582

7.  Laforin is a cell membrane and endoplasmic reticulum-associated protein tyrosine phosphatase.

Authors:  B A Minassian; D M Andrade; L Ianzano; E J Young; E Chan; C A Ackerley; S W Scherer
Journal:  Ann Neurol       Date:  2001-02       Impact factor: 10.422

8.  Targeted disruption of the Epm2a gene causes formation of Lafora inclusion bodies, neurodegeneration, ataxia, myoclonus epilepsy and impaired behavioral response in mice.

Authors:  Subramaniam Ganesh; Antonio V Delgado-Escueta; Toshiro Sakamoto; Maria Rosa Avila; Jesus Machado-Salas; Yoshinobu Hoshii; Takumi Akagi; Hiroshi Gomi; Toshimitsu Suzuki; Kenji Amano; Kishan Lal Agarwala; Yuki Hasegawa; Dong-Sheng Bai; Tokuhiro Ishihara; Tsutomu Hashikawa; Shigeyoshi Itohara; Eain M Cornford; Hiroaki Niki; Kazuhiro Yamakawa
Journal:  Hum Mol Genet       Date:  2002-05-15       Impact factor: 6.150

9.  Size-distribution analysis of macromolecules by sedimentation velocity ultracentrifugation and lamm equation modeling.

Authors:  P Schuck
Journal:  Biophys J       Date:  2000-03       Impact factor: 4.033

10.  Mutations in NHLRC1 cause progressive myoclonus epilepsy.

Authors:  Elayne M Chan; Edwin J Young; Leonarda Ianzano; Iulia Munteanu; Xiaochu Zhao; Constantine C Christopoulos; Giuliano Avanzini; Maurizio Elia; Cameron A Ackerley; Nebojsa J Jovic; Saeed Bohlega; Eva Andermann; Guy A Rouleau; Antonio V Delgado-Escueta; Berge A Minassian; Stephen W Scherer
Journal:  Nat Genet       Date:  2003-09-07       Impact factor: 38.330

View more
  7 in total

Review 1.  Remarkable evolutionary relatedness among the enzymes and proteins from the α-amylase family.

Authors:  Štefan Janeček; Marek Gabriško
Journal:  Cell Mol Life Sci       Date:  2016-05-06       Impact factor: 9.261

Review 2.  Lafora disease: from genotype to phenotype.

Authors:  Rashmi Parihar; Anupama Rai; Subramaniam Ganesh
Journal:  J Genet       Date:  2018-07       Impact factor: 1.166

3.  Molecular Architecture of the Inositol Phosphatase Siw14.

Authors:  Tyler J Florio; Ravi K Lokareddy; Richard E Gillilan; Gino Cingolani
Journal:  Biochemistry       Date:  2019-01-03       Impact factor: 3.162

Review 4.  Unique carbohydrate binding platforms employed by the glucan phosphatases.

Authors:  Shane Emanuelle; M Kathryn Brewer; David A Meekins; Matthew S Gentry
Journal:  Cell Mol Life Sci       Date:  2016-05-04       Impact factor: 9.261

5.  Oligomerization and carbohydrate binding of glucan phosphatases.

Authors:  Savita Sharma; Carl D Vander Kooi; Matthew S Gentry; Craig W Vander Kooi
Journal:  Anal Biochem       Date:  2018-10-03       Impact factor: 3.365

Review 6.  Glycogen metabolism in humans.

Authors:  María M Adeva-Andany; Manuel González-Lucán; Cristóbal Donapetry-García; Carlos Fernández-Fernández; Eva Ameneiros-Rodríguez
Journal:  BBA Clin       Date:  2016-02-27

7.  Abnormal glycogen chain length pattern, not hyperphosphorylation, is critical in Lafora disease.

Authors:  Felix Nitschke; Mitchell A Sullivan; Peixiang Wang; Xiaochu Zhao; Erin E Chown; Ami M Perri; Lori Israelian; Lucia Juana-López; Paola Bovolenta; Santiago Rodríguez de Córdoba; Martin Steup; Berge A Minassian
Journal:  EMBO Mol Med       Date:  2017-07       Impact factor: 12.137

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.